On-demand cancer immunotherapy via single-cell encapsulation of synthetic circuit–engineered cells
Science Advances · 2026
DOI: 10.1126/sciadv.aea3573 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2026. Verfasst von Yue Zhao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Henan Institute of Advanced Technology, School of Materials Science and Engineering, Zhengzhou University, Zhengzhou 450003, PR China. Hauptthemen laut MEDLINE: Immunotherapy, Neoplasms, Cell Engineering. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, International Postdoctoral Exchange Fellowship Program Talent Introduction Program, Scientific Research and Innovation Team of The First Affiliated Hospital of Zhengzhou University.
Abstract (Originalsprache)
Despite the therapeutic potential of engineered immune cell therapy against metastases, it faces challenges including cytokine-driven systemic toxicity, off-target biodistribution, and host rejection. Here, we develop red/far-red light-regulated individually encapsulated (RL/FRL-EnE) cells, integrating optogenetics with biomaterial encapsulation for precise immunomodulation. This system uses a phytochrome A–based photoswitch (ΔPhyA-PCB) that enables bidirectional control. RL (660 nanometers) triggers interferon-γ, interleukin-6, and anti-CD47 expression via ΔPhyA-PCB–far-red elongated hypocotyl 1 heterodimerization, while FRL (740 nanometers) rapidly reverses production, minimizing toxicity. Single-cell nanoencapsulation prevents intercellular cross-talk and immune clearance, enabling strict light-dependent regulation and extended tumor residence. In vivo, RL/FRL-EnE cells remodeled the tumor microenvironment, reducing immunosuppressive myeloid cells (1.3- to 1.7-fold), while enhancing dendritic cell (1.4-fold) and CD8 + T cell (2.8-fold) infiltration. Collectively, this work establishes a paradigm for closed-loop cellular immunotherapy, where light-regulated living therapeutics achieve on-demand immune reprogramming.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Henan Institute of Advanced Technology, School of Materials Science and Engineering, Zhengzhou University, Zhengzhou 450003, PR China.
- The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou 450052, PR China.
- Department of Biomedical Materials, Konyang University, Daejeon 35365 Republic of Korea.
- CAS Key Laboratory for Biomedical Effects of Nanomaterials & Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, China.
ORCID-Profile: Yue Zhao, Rui Li, Yirui Han, Chaochen Shi, Kyubae Lee, Guangjun Nie, Yazhou Chen
Förderung
- National Natural Science Foundation of China
- International Postdoctoral Exchange Fellowship Program Talent Introduction Program
- Scientific Research and Innovation Team of The First Affiliated Hospital of Zhengzhou University
- High level Talent International Training Project of Henan Province
Zitieren
APA
Zhao, Y., Li, R., Han, Y., Shi, C., Lee, K., Nie, G., & Chen, Y. (2026). On-demand cancer immunotherapy via single-cell encapsulation of synthetic circuit–engineered cells. Science Advances. https://doi.org/10.1126/sciadv.aea3573
Vancouver
Zhao Y, Li R, Han Y, Shi C, Lee K, Nie G, et al. On-demand cancer immunotherapy via single-cell encapsulation of synthetic circuit–engineered cells. Science Advances. 2026. doi:10.1126/sciadv.aea3573
BibTeX
@article{Zhao2026,
author = {Zhao, Yue and Li, Rui and Han, Yirui and Shi, Chaochen and Lee, Kyubae and Nie, Guangjun and Chen, Yazhou},
title = {On-demand cancer immunotherapy via single-cell encapsulation of synthetic circuit–engineered cells},
journal = {Science Advances},
year = {2026},
doi = {10.1126/sciadv.aea3573}
}
EUVIMED